The U.S. Food and Drug Administration (FDA) has advised that premature babies who receive Kaletra (lopinavir/ritonavir) oral solution may suffer from serious health problems. The solution contains the ingredients alcohol and propylene glycol. Premature babies are more likely to have a decreased ability to eliminate propylene glycol leading to adverse events such as serious heart, kidney, or breathing problems.
Kaletra oral solution is an antiviral medication used in combination with other antiretroviral drugs for the treatment of HIV-1 infection in pediatric patients 14 days of age (whether premature or full term) or older and in adults. Taking antiretroviral medications for HIV will not cure the infection, but can help children and adults with HIV-1 infection stay healthier for a longer period of time.
The use of Kaletra oral solution should be avoided in premature babies until 14 days after their due date, or in full-term babies younger than 14 days of age unless a healthcare professional believes that the benefit of using Kaletra oral solution to treat HIV infection immediately after birth outweighs the potential risks. In such cases, FDA strongly recommends monitoring for increases in serum osmolality, serum creatinine, and other signs of toxicity.
The attorneys at Messa & Associates are experienced at handling cases involving pharmaceutical and drug product injuries. Our extremely skilled team of attorneys and medical experts are dedicated to ensuring your family receives proper compensation to care for your child in the future. If you believe your child may have suffered injury as a result of being administered the Kaletra oral solution, please contact us at 1-877-MessaLaw.
No comments:
Post a Comment